Buy & Sell Ambarella Inc (AMBA) – Ambarella Inc Price Today
Global colorectal cancer diagnostics and therapeutics market to grow at ~9% CAGR, reaching $73B by 2034
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
AI in life sciences market set to grow at 20% CAGR, reaching $11.5B by 2034 driven by drug discovery and data analytics.
The global AI in life sciences market is projected to expand at a compound annual growth rate (CAGR) of about 20% from 2026 to 2034, reaching an estimated value of $11.5 billion. This growth is fueled by increasing demand for faster drug discovery, p...
New data shows Wegovy pill leads to significant long-term weight loss and improved physical function.
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...
Cerebras IPO signals market caution amid AI deployment delays and high valuations.
Cerebras Systems is set to go public with an IPO expected to value the company at over $50 billion, despite underlying operating losses. This IPO highlights market concerns as AI deployment at scale remains slow, with only 19% of companies reporting ...
Chinese solar firms cut U.S. stakes amid Trump-era subsidy cuts and IPO withdrawals signal tighter U.S.-China market controls.
Chinese solar manufacturers are reducing their ownership in U.S. operations due to new Trump administration rules limiting subsidies for China-linked solar panels made in the U.S. Companies like JinkoSolar are selling majority stakes in their U.S. su...
Eli Lilly's new drugs Foundayo and lower-dose Zepbound help sustain weight loss in obesity patients.
Eli Lilly released positive results from two late-stage obesity studies showing that patients maintained significant weight loss after switching to either Foundayo or a lower dose of Zepbound. The SURMOUNT-MAINTAIN trial showed continued weight loss ...
RoboStrategy stock drops 15% after initial surge and volatility halts post-Nasdaq debut
RoboStrategy, the first publicly traded closed-end fund focused on physical AI and robotics, saw its stock fall 15.35% on Wednesday after an initial surge fueled by retail investors. The fund launched on Nasdaq earlier this week, attracting heavy int...
AMD's $6.5M Marvell stake surges 66%, now worth $10.8M, highlighting AI chip market gains.
AMD disclosed a $6.5 million stake in Marvell Technology that has surged about 66% to an estimated $10.8 million, reflecting strong gains in AI-related semiconductor stocks. This investment underscores AMD's strategic exposure to key players in AI ha...
Nvidia earnings next week may impact S&P 500 more than Fed minutes due to AI spending focus.
Nvidia's upcoming earnings report is gaining importance as the company's market value and AI role grow, now surpassing the entire S&P 500 healthcare sector. Investors view Nvidia as a key indicator of AI spending, which is central to the current bull...
First patient dosed in Phase 1b trial of Sapu003, an IV everolimus for advanced mTOR-sensitive tumors
Sapu Nano and Oncotelic have dosed the first patient in a Phase 1b clinical trial of Sapu003, an intravenous formulation of everolimus designed to treat advanced mTOR-sensitive solid tumors such as HR+/HER2- breast cancer and renal cell carcinoma. Th...